An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Personalis to Participate at Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced cancer genomics, will participate in two upcoming investor conferences. The first is the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2023, at The Cliff Lodge in Snowbird, UT. The second is the 43rd Annual Cowen Healthcare Conference on March 7, 2023, at 10:30 a.m. Eastern Time at the Boston Marriott Copley Place in Boston, MA. Personalis is known for its NeXT Platform, which offers comprehensive insights into the human genome, aiding in precision cancer therapies. The company's laboratory is recognized for its clinical accuracy and quality.
Positive
None.
Negative
None.
FREMONT, Calif.--(BUSINESS WIRE)--
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the following investor conferences:
BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Participating on Thursday, February 16, 2023 at The Cliff Lodge in Snowbird, UT
43rd Annual Cowen Healthcare Conference Presenting on Tuesday, March 7, 2023 at 10:30 a.m. Eastern Time at the Boston Marriott Copley Place in Boston, MA
About Personalis, Inc.
Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis'Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit the Personalis website and News Center, and follow Personalis on LinkedIn and Twitter.
What investor conferences will Personalis (PSNL) participate in February and March 2023?
Personalis will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2023, and the Cowen Healthcare Conference on March 7, 2023.
Where will the 43rd Annual Cowen Healthcare Conference be held for Personalis (PSNL)?
The 43rd Annual Cowen Healthcare Conference will be held at the Boston Marriott Copley Place in Boston, MA.
When is Personalis (PSNL) presenting at the Cowen Healthcare Conference?
Personalis will present at the Cowen Healthcare Conference on March 7, 2023, at 10:30 a.m. Eastern Time.
What is the purpose of Personalis' NeXT Platform?
The Personalis NeXT Platform is designed to provide comprehensive insights into approximately 20,000 human genes, facilitating precision cancer therapies and diagnostics.
What is the significance of the BTIG MedTech conference for Personalis (PSNL)?
The BTIG MedTech conference is significant for Personalis as it provides an opportunity to engage with investors in the MedTech, Digital Health, and Life Science sectors.
